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2) two workshops in each country with a panel of local
influenza experts to validate the treatment patterns, to es-
timate missing values (event occurrences, transition prob-
abilities, hospitalization and indirect costs) and to ensure
the external validity of the local models. RESULTS: It
was possible to keep the general structure of the models
and to validate the basic assumptions. However, major
adaptations relating to influenza management and the as-
sociated costs were required. CONCLUSIONS: Even
though France, Germany and the UK have similar socio-
economic levels, the therapeutic and diagnostic manage-
ment of influenza differs between them. Indeed, the direct
transposition of a general model from one country to an-
other one is not possible: a cultural adaptation is re-
quired to make the model convincing, and therefore, use-
ful at a national policy level. These adaptations must
reflect differences in the patterns in service delivery, in in-
centives to patients and physicians, and in the propensity
to seek treatment.
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OBJECTIVE: Combination treatment with ribavirin and
interferon alpha-2b in treatment-naïve patients with chronic
hepatitis C virus produces an enhanced clinical response
compared with interferon alpha-2b treatment alone; add-
ing the second drug, however, will result in greater costs.
Clinical effects and costs for combination therapy were
compared to those for interferon alone in a cost-effective-
ness analysis for the Canadian healthcare environment.
METHODS: Data from an international clinical trial
comparing 24 and 48 weeks of combination therapy to
48 week interferon alone were applied to a previously
published model which tracked the health outcome of pa-
tients with chronic hepatitis C. Resource use and quality
of life was determined by a Canadian physician panel
and from patient-derived utility data; cost information in
1998 Canadian dollars was obtained from major health
centres across Canada and from published sources of Ca-
nadian cost data. RESULTS: Resource use by patients
with chronic hepatitis C can be minimal in the early
stages of the disease, progressing to hospitalization and
need for liver transplantation in the advanced stages. Ap-
plying dollar values to resource use, annual costs per dis-
ease state were found to range from under $200 per pa-
tient for the milder stages, up to greater than $90,000 per
patient for transplantation. For drug treatment, inter-
feron for 48 weeks cost $4,976 while combination ther-
apy for 24 weeks was $9,887 and for 48 weeks $12,840.
Modelling health outcomes over the course of the disease
along with costs for combination therapy compared to
interferon alone resulted in a marginal cost-effectiveness
ratio of $3,429 per discounted quality adjusted life year.
CONCLUSIONS: Results suggest that initial treatment
for chronic hepatitis C in Canada with 24 or 48 weeks of
combination therapy, when compared with 48 weeks of
interferon alone, should be cost-effective and economi-
cally attractive by conventional standards.
PID7
MULTITHERAPIES: TOWARDS COST-SAVING 
STRATEGIES IN REAL LIFE?
Le Pen C1, Rozenbaum W2, Downs A3, Lilliu H4, Maurel F4, 
Brun C5
1Dauphine University, Paris, France; 2Rothschild Hospital, Paris, 
France; 3European Center for the Epidemiological Monitoring 
of AIDS, St Maurice, France; 4CLP-Santé, Paris, France; 5Glaxo 
Wellcome, Marly-le-Roi, France
OBJECTIVE: To pragmatically assess the effect of
HAART strategy on effectiveness and cost among unse-
lected HIV-infected persons. METHOD: We compared
two groups of patients followed at Rothschild public
hospital in Paris. We extracted longitudinal data from a
random sample of 99 ART-naïve patients in which a
HAART treatment was initiated between 10/1/96 and 4/
1/97 (HAART group). Each patient of the HAART group
was randomly matched for age, sex and CD4 cell count
to a corresponding control patient entered in the data-
base before the introduction of HAART, between 10/1/
94 and 4/1/95 (CONTROL group), whatever the treat-
ment was. The comparison criteria, on a two-year period,
are survival rate, immune recovery rate (CD4 count), op-
portunistic infections and use of resources (ART, other
treatment costs and hospital costs). RESULTS: 2-year
survival curves are similar in both groups (P  0.1502,
Log-Rank test). Immune recovery rate, at the end of the
follow-up, is significantly higher among HAART pa-
tients, with 35% vs. 13% with a CD4 count above 500/
mm3. Both mean and median CD4 cell counts are greater
in HAART group (344/mm3 and 320/mm3 vs. 280/mm3
and 245/mm3 respectively). The mean cost of ART is
higher in HAART group (171%). Nevertheless, this fi-
nancial charge is fully balanced by savings in other treat-
ment costs (62% largely due to less opportunistic infec-
tion treatments) and reduction in hospital costs (25%).
CONCLUSION: We pragmatically compared two groups
of HAART-treated and non-HAART-treated patients, re-
gardless of their disease stage. Results show the benefit of
